Meloxicam protects against muscle and metabolic decline in ageing through Cdon restoration and oxidative stress modulation
Meloxicam (Mcam) is identified as a small molecule inducer of Cdon that enhances myogenic differentiation, increases muscle mass and function in young mice and mitigates age-related muscle atrophy, and is identified as a potential therapeutic target for age-associated skeletal muscle degeneration.